Biocon secures USFDA approval for Pebrilzo, its fifth cancer biosimilar
Biocon also said it has secured a global settlement and licence agreement with Genentech, allowing Pebrilzo's earliest licensed US launch in 2028.
We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Alembic Pharma receives USFDA approval for lung cancer drug Binimetinib business-standard.com